INTRODUCTION: Treatment of small cell lung cancer (SCLC) is initially gratifying with most patients responding to platinum-based chemotherapy. Treatment of relapsed disease gives much lower response rates of short duration. We undertook this study of the protein deacetylase inhibitor Romidepsin in chemosensitive recurrent SCLC based on preclinical data that suggested this to be an active target. METHODS: Patients had recurrent chemosensitive SCLC (relapse ≥90 days since completion of platinum-based chemotherapy). Treatment was administered as weekly infusions of Romidepsin at 13 mg/m(2) for 3 of 4 weeks. We designed a two-stage phase II study targeting a response rate of 30% (<10% response would be uninteresting and ≥30% worthy of further study). RESULTS: Sixteen patients (10 male, 6 female) were accrued to the first stage of this study. Most (11 patients, 69%) presented with extensive-stage SCLC, and all had received prior chemotherapy, with 11 having received prior radiation. Eastern Cooperative Oncology Group performance status was excellent with 0 in 6 patients (38%) and 1 in 10 patients. No objective responses were seen, and stable disease was the best response seen in 3 patients (19%). Toxicity was modest with 3 patients suffering grade 3 toxicity (lymphopenia, insomnia, nausea, vomiting, and hyponatremia) and one patient with grade 4 thrombocytopenia. Median progression-free survival was 1.8 months, and median overall survival was 6 months. CONCLUSION: Romidepsin given on a weekly schedule in patients with chemosensitive, recurrent SCLC was inactive and will not be pursued further in this setting.
INTRODUCTION: Treatment of small cell lung cancer (SCLC) is initially gratifying with most patients responding to platinum-based chemotherapy. Treatment of relapsed disease gives much lower response rates of short duration. We undertook this study of the protein deacetylase inhibitor Romidepsin in chemosensitive recurrent SCLC based on preclinical data that suggested this to be an active target. METHODS:Patients had recurrent chemosensitive SCLC (relapse ≥90 days since completion of platinum-based chemotherapy). Treatment was administered as weekly infusions of Romidepsin at 13 mg/m(2) for 3 of 4 weeks. We designed a two-stage phase II study targeting a response rate of 30% (<10% response would be uninteresting and ≥30% worthy of further study). RESULTS: Sixteen patients (10 male, 6 female) were accrued to the first stage of this study. Most (11 patients, 69%) presented with extensive-stage SCLC, and all had received prior chemotherapy, with 11 having received prior radiation. Eastern Cooperative Oncology Group performance status was excellent with 0 in 6 patients (38%) and 1 in 10 patients. No objective responses were seen, and stable disease was the best response seen in 3 patients (19%). Toxicity was modest with 3 patients suffering grade 3 toxicity (lymphopenia, insomnia, nausea, vomiting, and hyponatremia) and one patient with grade 4 thrombocytopenia. Median progression-free survival was 1.8 months, and median overall survival was 6 months. CONCLUSION:Romidepsin given on a weekly schedule in patients with chemosensitive, recurrent SCLC was inactive and will not be pursued further in this setting.
Authors: J von Pawel; J H Schiller; F A Shepherd; S Z Fields; J P Kleisbauer; N G Chrysson; D J Stewart; P I Clark; M C Palmer; A Depierre; J Carmichael; J B Krebs; G Ross; S R Lane; R Gralla Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: A Ardizzoni; H Hansen; P Dombernowsky; T Gamucci; S Kaplan; P Postmus; G Giaccone; B Schaefer; J Wanders; J Verweij Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: Nicholas A Vitanza; Matt C Biery; Carrie Myers; Eric Ferguson; Ye Zheng; Emily J Girard; Justyna M Przystal; Giulia Park; Alyssa Noll; Fiona Pakiam; Conrad A Winter; Shelli M Morris; Jay Sarthy; Bonnie L Cole; Sarah E S Leary; Courtney Crane; Nicole A P Lieberman; Sabine Mueller; Javad Nazarian; Raphael Gottardo; Mi-Youn Brusniak; Andrew J Mhyre; James M Olson Journal: Neuro Oncol Date: 2021-03-25 Impact factor: 12.300
Authors: Laleh Amiri-Kordestani; Victoria Luchenko; Cody J Peer; Kambiz Ghafourian; James Reynolds; Deb Draper; Robin Frye; Sue Woo; David Venzon; John Wright; Monica Skarulis; William D Figg; Tito Fojo; Susan E Bates; Richard L Piekarz Journal: Clin Cancer Res Date: 2013-06-11 Impact factor: 12.531
Authors: Roisin M Connolly; Eric Laille; Ulka Vaishampayan; Vincent Chung; Karen Kelly; Afshin Dowlati; Olatunji B Alese; R Donald Harvey; Paul Haluska; Lillian L Siu; Shivaani Kummar; Richard Piekarz; S Percy Ivy; Nicole M Anders; Melinda Downs; Ashley O'Connor; Angela Scardina; Jacqueline Saunders; Gary L Rosner; Michael A Carducci; Michelle A Rudek Journal: Clin Cancer Res Date: 2020-08-14 Impact factor: 12.531
Authors: Zibo Zhao; Aileen P Szczepanski; Natsumi Tsuboyama; Hiam Abdala-Valencia; Young Ah Goo; Benjamin D Singer; Elizabeth T Bartom; Feng Yue; Lu Wang Journal: Cancer Res Date: 2021-08-02 Impact factor: 12.701